27 related articles for article (PubMed ID: 19597729)
1. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Koukourakis MI; Giatromanolaki A; Kakolyris S; Froudarakis M; Georgoulias V; Retalis G; Bahlitzanakis N
Med Oncol; 2000 May; 17(2):135-43. PubMed ID: 10871820
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Activities of Interleukin-12 in Melanoma.
Gao W; Pan J; Pan J
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428682
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin Treatment Alters Systemic Immune Responses.
Stojanovska V; Prakash M; McQuade R; Fraser S; Apostolopoulos V; Sakkal S; Nurgali K
Biomed Res Int; 2019; 2019():4650695. PubMed ID: 30906773
[TBL] [Abstract][Full Text] [Related]
4. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.
Kaufman HL; Ruby CE; Hughes T; Slingluff CL
J Immunother Cancer; 2014; 2():11. PubMed ID: 24971166
[TBL] [Abstract][Full Text] [Related]
5. XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
Hatch SB; Swift LP; Caporali S; Carter R; Hill EJ; MacGregor TP; D'Atri S; Middleton MR; McHugh PJ; Sharma RA
Int J Cancer; 2014 Mar; 134(6):1495-503. PubMed ID: 23982883
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model.
Roda JM; Wang Y; Sumner LA; Phillips GS; Marsh CB; Eubank TD
J Immunol; 2012 Sep; 189(6):3168-77. PubMed ID: 22869907
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis.
Roda JM; Sumner LA; Evans R; Phillips GS; Marsh CB; Eubank TD
J Immunol; 2011 Aug; 187(4):1970-6. PubMed ID: 21765015
[TBL] [Abstract][Full Text] [Related]
8. DNA interstrand crosslink repair and cancer.
Deans AJ; West SC
Nat Rev Cancer; 2011 Jun; 11(7):467-80. PubMed ID: 21701511
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.
Hoeller C; Michielin O; Ascierto PA; Szabo Z; Blank CU
Cancer Immunol Immunother; 2016 Sep; 65(9):1015-34. PubMed ID: 27372293
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.
Forcello NP; Khubchandani S; Patel SJ; Brahaj D
J Oncol Pharm Pract; 2015 Apr; 21(2):148-56. PubMed ID: 24500808
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
Locke F; Clark JI; Gajewski TF
Cancer Chemother Pharmacol; 2010 Feb; 65(3):509-14. PubMed ID: 19597729
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
13. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
